Semaglutide vs Tirzepatide
The two biggest names in GLP-1 weight loss therapy, compared head-to-head with clinical trial data from STEP and SURMOUNT programs.
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Brand Names | Ozempic, Wegovy, Rybelsus | Mounjaro, Zepbound |
| Mechanism | GLP-1 receptor agonist | Dual GLP-1/GIP agonist |
| Max Weight Loss | ~16.9% (STEP 1) | ~22.5% (SURMOUNT-1) |
| A1C Reduction | ~1.5–1.8% | ~2.0–2.3% |
| Dosing | Weekly injection (0.25–2.4 mg) | Weekly injection (2.5–15 mg) |
| FDA Approved | ✅ (T2D 2017, Obesity 2021) | ✅ (T2D 2022, Obesity 2023) |
| Cost (Cash Pay) | $900–$1,600/mo | $1,000–$1,200/mo |
| Key Trial | STEP program | SURMOUNT program |
Mechanism of Action
Semaglutide — The GLP-1 Pioneer
Semaglutide mimics the natural hormone GLP-1 (glucagon-like peptide-1), which is released after eating. It works through a single receptor to:
- Slow gastric emptying — food stays in the stomach longer, increasing satiety
- Reduce appetite — acts on brain areas that control hunger and food reward
- Enhance insulin secretion — only when blood sugar is elevated (glucose-dependent)
- Suppress glucagon — reduces liver glucose output
Tirzepatide — The Dual Agonist
Tirzepatide targets two receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This dual mechanism provides:
- Everything semaglutide does via the GLP-1 pathway
- Enhanced insulin sensitivity through the GIP pathway
- Improved fat metabolism — GIP signaling in adipose tissue may enhance fat mobilization
- Potentially better tolerability — GIP may partially counterbalance GLP-1 nausea signals
💡 Why Does Dual Agonism Matter?
Think of GLP-1 as the appetite brake and GIP as the metabolic accelerator. Semaglutide applies the brake. Tirzepatide applies the brake and hits the accelerator on fat metabolism simultaneously. This dual action likely explains why tirzepatide shows greater weight loss in clinical trials.
Efficacy: Weight Loss & Blood Sugar
Weight Loss Data
STEP 1 (semaglutide 2.4 mg, 68 weeks, n=1,961): Mean weight loss of 14.9% with 1/3 of participants losing ≥20% body weight.
SURMOUNT-1 (tirzepatide 15 mg, 72 weeks, n=2,539): Mean weight loss of 22.5% with over half of participants losing ≥20% body weight.
Direct comparison: While not head-to-head in the same trial, tirzepatide at maximum dose shows approximately 5–7 percentage points greater weight loss than semaglutide at maximum dose. The SURMOUNT-5 trial confirmed tirzepatide's superiority head-to-head.
A1C Reduction (Type 2 Diabetes)
For patients with type 2 diabetes:
- Semaglutide 1 mg (Ozempic): Reduces A1C by approximately 1.5–1.8% from baseline
- Tirzepatide 15 mg (Mounjaro): Reduces A1C by approximately 2.0–2.3% from baseline
In the SURPASS-2 trial, tirzepatide achieved A1C <5.7% (non-diabetic range) in up to 46% of participants, compared to about 19% on semaglutide 1 mg.
Dosing Schedule
Both are administered as once-weekly subcutaneous injections with gradual dose escalation to minimize GI side effects.
Semaglutide Titration
- Weeks 1–4: 0.25 mg/week
- Weeks 5–8: 0.5 mg/week
- Weeks 9–12: 1.0 mg/week
- Weeks 13–16: 1.7 mg/week
- Week 17+: 2.4 mg/week (maintenance)
Tirzepatide Titration
- Weeks 1–4: 2.5 mg/week
- Weeks 5–8: 5 mg/week
- Weeks 9–12: 7.5 mg/week
- Weeks 13–16: 10 mg/week
- Weeks 17–20: 12.5 mg/week
- Week 21+: 15 mg/week (maximum)
Tirzepatide has a slightly longer titration to maximum dose (20 weeks vs 16 weeks), but many patients achieve significant results before reaching the highest dose.
Side Effect Profile
Both medications share a similar side effect profile due to their shared GLP-1 activity. The most common adverse events are gastrointestinal:
| Side Effect | Semaglutide | Tirzepatide |
|---|---|---|
| Nausea | ~44% | ~26–33% |
| Diarrhea | ~30% | ~21–25% |
| Vomiting | ~24% | ~12–18% |
| Constipation | ~24% | ~17–20% |
| Injection Site Rx | ~3–5% | ~3–7% |
⚠️ Serious Risks (Both)
Both carry a boxed warning for thyroid C-cell tumors (observed in rodent studies). They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2. Rare cases of pancreatitis have been reported with both medications.
Cost Comparison
Pricing can vary significantly based on insurance coverage, manufacturer programs, and pharmacy.
| Category | Semaglutide | Tirzepatide |
|---|---|---|
| Brand Cash Pay | $900–$1,600/mo | $1,000–$1,200/mo |
| With Insurance | $0–$300/mo (varies) | $0–$300/mo (varies) |
| Manufacturer Program | Novo Nordisk savings card | Lilly savings card |
Note: Compounded semaglutide has been widely available through telehealth platforms at lower prices. The FDA's compounding policies continue to evolve — check current availability with your provider.
Clinical Trial Summary
STEP Program (Semaglutide)
The STEP (Semaglutide Treatment Effect in People with obesity) program included multiple Phase 3 trials:
- STEP 1: 14.9% mean weight loss vs 2.4% placebo (68 weeks)
- STEP 2: 9.6% in T2D patients (lower response typical in diabetic populations)
- STEP 3: 16% with intensive behavioral therapy + semaglutide
- STEP 5: Weight loss maintained through 2 years of treatment
SURMOUNT Program (Tirzepatide)
The SURMOUNT program studied tirzepatide for obesity:
- SURMOUNT-1: 22.5% mean weight loss at 15 mg dose (72 weeks)
- SURMOUNT-2: 14.7% in T2D patients (72 weeks)
- SURMOUNT-3: 26.6% with intensive lifestyle intervention + tirzepatide
- SURMOUNT-5: Head-to-head vs semaglutide — tirzepatide showed statistically superior weight loss
⚖️ The Verdict: Which One Is Right for You?
- You want a well-established medication with the longest track record
- You prefer an oral option (Rybelsus) — tirzepatide is injection-only
- Cost/access is a factor and compounded semaglutide is available in your area
- Your insurance covers Ozempic/Wegovy but not Mounjaro/Zepbound
- You want the highest possible weight loss efficacy based on trial data
- You've plateaued on semaglutide or a similar GLP-1 agonist
- You have type 2 diabetes and want the strongest A1C reduction
- GI side effects concern you — tirzepatide may have a slightly better GI profile
Both are excellent, FDA-approved options. Tirzepatide's dual mechanism gives it an edge in raw efficacy, but semaglutide has a longer track record and more formulation options. The best choice depends on your insurance coverage, treatment goals, and how your body responds. Work with your healthcare provider to decide.
Frequently Asked Questions
Clinical trials show tirzepatide produces greater average weight loss (up to 22.5% in SURMOUNT-1) compared to semaglutide (up to 16.9% in STEP 1). However, individual responses vary significantly, and both are effective FDA-approved options.
Semaglutide is a GLP-1 receptor agonist (single mechanism), while tirzepatide is a dual GLP-1/GIP receptor agonist. This dual action is believed to contribute to tirzepatide's greater efficacy for both weight loss and blood sugar control.
Without insurance, brand-name semaglutide (Wegovy/Ozempic) costs approximately $900–$1,600/month, while tirzepatide (Mounjaro/Zepbound) costs approximately $1,000–$1,200/month. Compounded versions, where available, may cost less.
Both share similar GI side effects (nausea, vomiting, diarrhea, constipation). Tirzepatide may have slightly lower nausea rates at comparable efficacy levels. Both carry rare risks of pancreatitis and thyroid C-cell tumors (boxed warning).
Yes, switching is possible and sometimes recommended when patients plateau on semaglutide. The transition should be managed by a healthcare provider, typically starting tirzepatide at the lowest dose after discontinuing semaglutide.
Explore More Peptide Tools
Check interactions and calculate dosing for GLP-1 medications